Tubulin is a molecular target of the Wnt-activating chemical probe

Yasunori Fukuda, Osamu Sano, Kenichi Kazetani, Koji Yamamoto, Hidehisa Iwata* and Junji Matsui*

Abstract

Background: In drug discovery research, cell-based phenotypic screening is an essential method for obtaining potential drug candidates. Revealing the mechanism of action is a key step on the path to drug discovery. However, elucidating the target molecules of hit compounds from phenotypic screening campaigns remains a difficult and troublesome process. Simple and efficient methods for identifying the target molecules are essential.

Results: 2-Amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine (AMBMP) was identified as a senescence inducer from a phenotypic screening campaign. The compound is widely used as a Wnt agonist, although its target molecules remain to be clarified. To identify its target proteins, we compared a series of cellular assay results for the compound with our pathway profiling database. The database comprises the activities of compounds from simple assays of cellular reporter genes and cellular proliferations. In this database, compounds were classified on the basis of statistical analysis of their activities, which corresponded to a mechanism of action by the representative compounds. In addition, the mechanisms of action of the compounds of interest could be predicted using the database. Based on our database analysis, the compound was anticipated to be a tubulin disruptor, which was subsequently confirmed by its inhibitory activity of tubulin polymerization.

Conclusion: These results demonstrate that tubulin is identified for the first time as a target molecule of the Wnt-activating small molecule and that this might have misled the conclusions of some previous studies. Moreover, the present study also emphasizes that our pathway profiling database is a simple and potent tool for revealing the mechanisms of action of hit compounds obtained from phenotypic screenings and off targets of chemical probes.
chemical syntheses to add tags to compounds of interest without deteriorating their activities. To determine the target molecules of compounds without affinity tags, Petrone et al. developed the chemical biological descriptor “high-throughput screening finger-print (HTS-FP)” that employs accumulated HTS data [8]. On the other hand, Frederick et al. developed a screening platform that consists of a series of reporter gene assays to disclose the mechanisms of action (MOAs) of compounds and by conducting assays in a quantitative HTS format [9, 10]. To develop a much simpler target identification approach with tag-free compounds, we exploited a pathway profiling database using only tens of cellular assays representing cellular signaling cascades through evaluation of compounds at a single concentration.

Oncology has become one of the largest therapeutic areas in the pharmaceutical industry. Various kinds of molecular targets and cellular signals have been reported to inhibit cancer growth. Among them, cellular senescence is considered to be the most important cellular phenotype for permanently arresting the cell cycle [11]. To date, reports have shown that genetic mutations and cellular stressors such as oxidative stress enhance cellular senescence and that some small molecules induce cellular senescence [12, 13]. In particular, compounds that induce cellular senescence are expected to be potent drugs for suppressing cancer growth [14]. Here we conducted a phenotypic screening campaign based on high-content cellular imaging to probe small molecules that induce cellular senescence.

**Results**

**Pathway profiling database classifies compounds according to their MOA**

The pathway profiling database mainly comprises reporter gene assays using firefly luciferase that cover 13 different signaling pathways and cellular proliferation assays with 7 commercially available cell lines (Table 1). These types of cellular assays are widely used in cell biology research and are highly accessible because of their simple procedures and low cost. In addition, these assays are very robust and demonstrate high throughput, which enabled us to detect subtle signal changes in an HTS-compatible format. The assays were functionally validated using the dose-dependent response of a natural ligand or known inhibitors/activators.

| Table 1 Constituents of the pathway profiling database. The types of cellular signals for the reporter gene assays and cell lines of the proliferation assays are shown |
|-----------------|-----------------|
| Cellular reporter gene assays | Cellular proliferation assays |
| cAMP response element (CRE) signal | HEX293T |
| Nuclear factor of activated T-cells (NFAT) signal | MRC5 (high density) |
| Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signal | MRC5 (low density) |
| Serum response element (SRE) signal | AS49 |
| Serum response factor (SRF) signal | PC3 |
| p53 signal | LNCaP |
| E2F signal | Jurkat |
| Activating transcription factor 6 signal | MDA-MB-231 |
| Hedgehog signal | |
| Hypoxia-inducible factor 1 (HIF1) signal | |
| Nuclear factor erythroid 2-related factor 2 (Nf2) signal | |
| SMAD signal | |
| Wnt signal | |

As a result of the hierarchical clustering analysis, compounds that had similar activities in most assays were classified into the same cluster, enabling us to visually determine that they have similar molecular targets and signaling pathways.

Forskolin (Fig. 2), an adenylate cyclase activator [15], was included in each library, and all were grouped into one cluster (Fig. 1b). In the cluster, N-ethylcarboxamidoadenosine (NECA) (Fig. 2), an adenosine receptor agonist [16], was also included. This cluster was shown to gather compounds stimulating cAMP production via adenylate cyclase activation. This result indicates that the pathway profiling database classifies compounds according to their MOA. Similarly, phorbol 12-myristate 13-acetate (PMA) [17] and its structural analogs phorbol 12,13-dibutyrate [18], 13-O-acetylphorbol [19], and 12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA) [20] (Fig. 2) were classified into the same cluster (Fig. 1c). In other words, the structural analogs that had the same effect on cellular signaling were categorized into one cluster, as expected.

Following these analyses, we investigated structurally diverse compounds that affect the same target proteins. We focused on the phosphodiesterase (PDE) inhibitors [21–24] (Fig. 2) contained in our database. To quantitatively compare differences in the structures and activities of each compound in our database, we employed Tanimoto structural similarity calculated by Daylight’s fingerprints and Pearson’s correlation coefficients (activity versus activity), respectively. The Tanimoto similarities ranged from 0.16 to 0.65, strongly indicating the broad structural diversity between the compounds in our database (Fig. 1d). In contrast,
Fig. 1 (See legend on next page.)
Fig. 1 Analysis of the pathway profiling database. a The heat map was visualized with TIBCO Spotfire software for clustering analysis. This figure represents the entire heat map of the pathway profiling database. The activities of each assay are displayed as a gradient from minimum activities (blue) to maximum activities (red). For details of the assay lists, see Table 1. b This cluster contained forskolin derived from each commercial compound library and NECA, a potent adenosine receptor agonist. c PMA and its structural analogs were grouped in the cluster shown. d The Tanimoto structural similarities and Pearson’s correlation coefficients (activity versus activity) were calculated for PDE4 inhibitors.

Fig. 2 Chemical structures of the compounds discussed in this study.
Pearson’s correlation coefficients (activity versus activity) in our database ranged from 0.64 to 0.83 (Fig. 1d), showing their high bioactive similarities, despite their low structural similarities. These results indicate that our pathway profiling database based on the biological activities of compounds led to classifications corresponding to not only their structural similarities but also their MOAs.

Wnt-activating small molecule is identified as a cellular senescence inducer

Triple-negative breast cancer has been a focus among the various cancer classes because of its lack of response to hormonal therapies, and new drugs with distinct MOAs are absolutely required to cure breast cancer patients [25]. Therefore, we employed MDA-MB-231 cells with triple-negative features to obtain cellular senescence inducers as anticancer agents [26]. In this strategy, we performed phenotypic screening on the basis of high-content cellular imaging, which is a very useful method to analyze altered cellular morphology. The cellular senescence morphology was reported to lead to a topologically enlarged appearance [11]. Sodium butyrate is a well-known senescence inducer [27], and we confirmed that it provoked the reported senescence phenotype in MDA-MB-231 cells and expanded cell shapes (Fig. 3a). In our study, this cellular morphology was defined as an indicator of cellular senescence.

**Fig. 3** A cell-based assay for a screening campaign of cellular senescence morphology inducers by fluorescence microscopy. **a** MDA-MB231 cells were treated with 1 mM sodium butyrate. Hoechst 33342 was used as a nuclear marker (blue) and CMFDA was used to mark cytosols (green). Scale bar, 10 μm. **b** A compound selection scheme for the discovery of senescence inducers. AMBMP was obtained as a hit compound through the screening campaign. **c** Hit compound results from the screening campaign. Fold changes in the cellular area at 3 μM concentrations were calculated for the compounds with a custom-made image analysis algorithm. **d** Activity of the Wnt reporter gene assay with a potent GSK3β inhibitor, SB216763, and AMBMP is shown. The results are the mean of 3 replicate experiments (mean ± SD). **e** MDA-MB231 cells were treated with 3 μM SB216763, 3 μM AMBMP, and 1 mM sodium butyrate. Hoechst 33342 was used as a nuclear marker (blue) and CMFDA was used to mark cytosols (green). Scale bar, 10 μm.
For high-content screening (HCS) of senescence inducers, we developed a cell-based assay to analyze cellular phenotypic changes in MDA-MB-231 cells. To determine the activities of compounds in this HCS, the cellular area, which plays a key role in the selection of senescence inducers, was calculated using a custom-made image analysis algorithm. We screened 1408 compounds in Tocriscreen (TOCRIS Bioscience) and StemSelect Small Molecule Regulators (Merck Millipore) at concentrations of 3 μM and obtained 20 compounds that induced a ≥2-fold enlargement of the cytosolic area (Fig. 3b). Of these 20 compounds identified as senescence inducers (Fig. 3c), molecular targets of 19 compounds have been clarified in past studies, but that of 2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine (AMBMP) (Fig. 2) has not been revealed yet. Thus, we focused on AMBMP to elucidate its molecular target, which is described further in this report.

It is generally considered that Wnt signaling pathways play important roles during embryonic development [28]. AMBMP was first identified as a Wnt signal agonist through Wnt signal activator screening using a common reporter gene assay [29]. To date, the first report of AMBMP has been cited in 68 papers, and the compound itself and its 10 applications have been patented (SciFinder®). However, its binding proteins have not yet been identified. We initially measured the activity of AMBMP using a Wnt reporter gene assay, as reported previously by Liu et al. [29]. Unexpectedly, using the Wnt reporter assay, we detected a much lower efficacy of AMBMP than that of a widely known Wnt signal activator glycogen synthase kinase 3β (GSK3β) inhibitor (SB216763) [30] (Figs. 2 and 3d). In contrast, GSK3β inhibitors were not observed to induce the senescence morphology (Fig. 3e, Additional file 1: Figure S1). These results strongly suggest that Wnt signal activation is not directly related to its cellular senescence and that AMBMP has binding proteins responsible for inducing cellular senescence.

Pathway profiling database identifies tubulin as a target protein of AMBMP
To identify an AMBMP target molecule, we compared the cellular assays with our pathway profiling database and calculated each Pearson’s correlation coefficient (activity versus activity) between AMBMP and other all compounds in our database. As a result, 12 compounds demonstrated values above 0.8, which indicated high similarities (Fig. 4a). Moreover, 10 of the 12 compounds involved classical tubulin disruptors such as nocodazole (Fig. 2) and were thus known from previous reports to bind to tubulin [31–33]. Of these 10 compounds, only 2, KF 38789 and chromoeceptin, had not been reported to induce tubulin depolymerization. The analyzed data allowed us to predict that AMBMP would directly interact with tubulin.

To test this hypothesis, we measured the tubulin disruption activity of AMBMP in a tubulin polymerization assay. Consequently, tubulin polymerization was detected by fluorescence enhancement following uptake of a fluorescent reporter molecule into the polymerized tubulin during polymerization [34]. We observed tubulin polymerization inhibition by AMBMP and nocodazole with IC₅₀ values of 0.33 μM and 0.34 μM, respectively (Fig. 4b, Additional file 1: Figure S2A). In this fluorescence-based polymerization assay, AMBMP was confirmed not to mediate the fluorescence interference through the observation of its UV–vis and fluorescence spectrum (Additional file 1: Figure S3). In addition, intrinsic fluorescence quenching was used to study the potential interaction between AMBMP and tubulin. The fluorescence intensity of tubulin was decreased gradually with increasing concentrations of AMBMP, confirming its binding to tubulin. (Fig. 4c). To determine the effects of these 2 compounds on the cellular microtubule network, we conducted a cell-based assay using cellular imaging techniques and fluorescent staining of tubulin. In the confocal image analysis, AMBMP and nocodazole were observed to clearly disrupt the intracellular microtubule network compared to control and SB216763-treated cells (Fig. 5A). Disturbance of the microtubule network by AMBMP and nocodazole was detected with IC₅₀ values of 0.34 μM and 1.7 μM, respectively (Additional file 1: Figure S2B). Furthermore, AMBMP as well as nocodazole was observed to inhibit cell proliferation and induce a cell cycle arrest in MDA-MB-231 cells (Additional file 1: Figure S4A, S4B). The effect of AMBMP on mitotic spindles was also observed with slightly shortening the spindle and astral microtubule at the low concentration of 30 nM and with significantly disrupting mitotic spindles at the higher concentrations of 0.3 and 3 μM (Fig. 5b), which was consistent with previous reports showing the effect of microtubule disruptors on mitotic spindles [35]. These results indicate that AMBMP had a strong inhibitory effect on tubulin polymerization, comparable to that of nocodazole. In addition, we had previously observed in our screening campaign that common tubulin disruptors induce cellular senescence (Fig. 3c) [36, 37].

Discussion
In our study, the pathway profiling database based on the biological activities of compounds was confirmed to lead to classifications corresponding to both their structural similarities and their MOAs. Through operating the system, we will both maintain and obtain data at a lower cost and in a shorter period than the HTS-FP database and BioMAP™ (DiscoveRx), in which primary cells were utilized. However, our prediction method is limited to the range of target molecules of the reference compounds; however, to overcome this limitation, we will add various reference data for
compounds that affect different types of target proteins other than those of the current compounds. In general, the accuracy of clustering analysis increases with a larger collection of datasets. Therefore, we will expand the cellular assays in the pathway profiling database to improve the accuracies of predicting both target molecules and cellular signaling properties. With these improvements in our system, we are attempting to perform target identification of other compounds, including our in-house compounds, with unknown targets.

In addition, we estimated the extent of cellular signaling pathways covered by our database through a computational approach. With Reactome Pathway Database [38], our pathway profiling database has the potential to detect cellular events involved in more than 200 canonical biological pathways. Moreover, 70% of the tested compounds with well-characterized MOAs had detectable activity in at least one assay in our database. Consequently, our simple system is a promising and cost-effective tool for profiling phenotypes and for predicting molecular targets of hit compounds from PDD.

By applying our profiling system for target identification of AMBMP, we have revealed that AMBMP is a tubulin disrupting molecule for the first time since the compound was reported as a Wnt agonist. The Tanimoto similarities between AMBMP and tubulin disruptors ranged from 0.12 to 0.26 (Fig. 4a), which means that these compounds are apparently not structural analogs of AMBMP. Because of their low scores, the structural similarities did not lead us to hypothesize whether AMBMP could inhibit tubulin
polymerization. The achievement of AMBMP target identification supports the result that our pathway profiling database was extremely useful for predicting various pharmacological targets of compounds with unknown mechanisms. On the other hand, we consider that it is important to reveal the molecular mechanisms inhibiting tubulin polymerization by AMBMP. To address the issue, in future study, we will clarify its binding site on tubulin through a cocrystal structural analysis for AMBMP and tubulin complex.

Chemical probes are widely used to demonstrate target molecule proof-of-concept in drug discovery [39]. To this end, the selectivity of chemical probes against the intended targets is a key factor. If these chemical probes interact with unintentional molecules and induce cellular phenotypes through their off-target effects, then both time and money might be lost in the process of drug discovery research. Some past research that used AMBMP as a chemical probe for Wnt signal activation might have incorrectly generated misleading results due to inhibition of tubulin activity. Recently, the met proto-oncogene (c-MET) inhibitor tivantinib was confirmed to inhibit tubulin polymerization as well as AMBMP [40]. Through our study, KF 38789 and chromoceptin were also shown to have similar bioactive profiles to tubulin disruptors (Fig. 4b), generating the possibility that both compounds interact with tubulin. These compounds will be the subject of a future publication. In addition, a previous report revealed that the structural similarities of compounds do not provide sufficient information to speculate on their biological activities [41]. For an efficient drug discovery process, it is important to evaluate and profile chemical probes using various types of cellular assays, such as our pathway profiling database.

**Conclusion**

Our pathway profiling database determined tubulin to be a target of AMBMP, which was unknown since the discovery of AMBMP, and our simple and efficient system proved to be a powerful method for predicting compound MOAs. AMBMP has been widely used as a chemical probe for Wnt signal activation, but the results for studies that used the compound might have been influenced by its modulation of tubulin activity and not Wnt signal activity. For proper utilization of chemical probes, it is potentially valuable to investigate their cellular profiles using multiple cellular assays, such our pathway profiling database, which provides beneficial information about representative cellular signaling processes. Moreover, in drug discovery, off-target interactions are strongly thought to lead to low efficacy and significant side effects in clinical trials; therefore, the development of target identification and prediction methods is now definitively required to determine not only on-target molecules but also off-target molecules. The system will certainly keep providing us with useful information.

---

**Fig. 5** Effect of AMBMP on the cellular tubulin network and mitotic spindles. (A) The cellular tubulin network (green) was observed by fluorescence microscopy. Hoechst 33342 was used as a nuclear marker (blue). (a) control. (b) 3 μM SB216763. (c) 3 μM AMBMP. (d) 3 μM Nocodazole. Scale bar, 10 μm. (B) Control and compounds-treated MDA-MB-231 cells were stained with α-tubulin (green), phospho-histone H3 (red), and nuclei (blue). Phosphorylation at a highly conserved serine residue (Ser10) in the histone H3 is a key marker during the mitotic phase of the cell cycle. (a) control. (b) 30 nM nocodazole. (c) 0.3 μM nocodazole. (d) 3 μM nocodazole. (e) 30 nM AMBMP. (f) 0.3 μM AMBMP. (g) 3 μM AMBMP. Scale bar, 10 μm.
for various stages of the drug discovery process through target prediction and drug safety research.

**Methods**

**Chemical compounds**

Tocriscreen (TOCRIS Bioscience), Natural Product Library (ENZO Life Sciences), and StemSelect Small Molecule Regulators (Merck Millipore) were all dissolved in DMSO (10 mM for Tocriscreen and StemSelect and 10 mg/mL for the Natural Product Library). AMBMP was obtained from Merck Millipore. Sodium butyrate, nocodazole, and SB216763 were sourced from Wako.

**Cell cultures**

HEK293T, MRC5, A549, PC3, LNCaP, Jurkat, MDA-MB231, NIH-3 T3, and SW480 cells were purchased from ATCC. HEK293T, A549, MRC5, and MDA-MB-231 cells were cultured in DMEM containing 4.5 g/L glucose, 10% fetal bovine serum (FBS), and penicillin/streptomycin. Jurkat, LNCaP, SW480, and PC3 cells were cultured in RPMI 1640 media containing 10% FBS and penicillin/streptomycin. NIH-3 T3 cells were cultured in DMEM containing 1.5 g/L glucose, 10% FBS, and penicillin/streptomycin. All cell culture reagents were purchased from Wako.

**Reporter gene assays in pathway profiling**

We developed reporter gene assays using a firefly luciferase system purchased from Promega. Detailed assay conditions such as cell lines, cell densities, corresponding ligands, incubation time with compounds, and materials are shown (Table 2). All assays were performed in a 384-well plate format. Plasmids were constructed by inserting each response element sequence at a multi-cloning site upstream from firefly luciferase. Transient transfections of all plasmids were performed in corresponding cell lines with Fugene HD (Promega) according to the manufacturer’s instructions. In each assay, we validated the assay condition with its ligand to perform a stable screening campaign (data not shown). In all assays, all compounds were diluted in complete media at a concentration of 3 μg/mL (Natural Product Library) and 3 μM (other libraries) and treated for the appropriate durations. After the addition of Steady-Glo (Promega) according to the manufacturer’s instructions, luminescence signals were measured using a luminescence plate reader (EnVision; PerkinElmer). We typically obtained 2 parameters calculated from each assay: one was

| Cellular signal | Cell lines | Cell density (cells/well) | Ligand | Incubation time with compounds | Original materials or references |
|----------------|------------|--------------------------|--------|-------------------------------|-------------------------------|
| cAMP response element (CRE) signal | HEK293T | 5,000 | Forskolin (1 μM) | 5 h | pGL4.29 (Promega) |
| Nuclear factor of activated T-cells (NFAT) signal | HEK293T | 5,000 | Ionomycin (1 μM) PMA (10 ng/mL) | 5 h | pGL4.30 (Promega) |
| Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signal | HEK293T | 10,000 | TNFα (3 ng/mL) | 20 h | pGL4.32 (Promega) |
| Serum response element (SRE) signal | HEK293T | 20,000 | FBS (15 μM) PMA (30 ng/mL) | 20 h | pGL4.33 (Promega) |
| Serum response factor (SRF) signal | HEK293T | 20,000 | FBS (15 μM) | 5 h | pGL4.34 (Promega) |
| p53 signal | HEK293T | 10,000 | Doxorubicin (1 μM) | 20 h | [43] |
| E2F signal | HEK293T | 20,000 | FBS (15 μM) | 20 h | [44] |
| Activating transcription factor 6 signal | HEK293T | 5,000 | Thapsigargin (30 nM) | 5 h | [45] |
| Hedgehog signal | NIH3T3 | 7,500 | mouse sonic hedgehog | 20 h | [46] |
| Hypoxia-inducible factor 1 (HIF1) signal | HEK293T | 10,000 | hypoxia | 20 h | [47] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) signal | HEK293T | 5,000 | tert-butyldihydroquinone (20 μM) | 20 h | pGL4.37 (Promega) |
| SMAD signal | HEK293T | 10,000 | TGFβ (0.2 ng/mL) | 20 h | [48] |
| Wnt signal | HEK293T | 10,000 | Wnt3a | 20 h | [49] |
| Wnt signal | SW480 | 10,000 | no ligand (constitutive active) | 20 h | [49] |
| IL17 signal | Jurkat | 5,000 | Ionomycin (400 nM) PMA (4 ng/mL) | 5 h | [50] |
the compound’s inhibitory activity with ligand activation and the other was its agonistic activity without ligand activation.

**Cellular proliferation assays used in pathway profiling**

Cell lines, cell densities, and incubation times with compounds are shown (Table 3). Cellular proliferation was detected with CellTiter-Glo (Promega). All assays were performed in a 384-well plate format. Luminescence signals were readout using a luminescence plate reader (EnVision; PerkinElmer). The proliferation assays with HEK293T cells and Jurkat cells were used as the counter-screen against reporter gene assays.

**Cell-based phenotypic assays for cellular senescence inducers**

MDA-MB231 cells were seeded in a 384-well plate (3000 cells/well) for 20 h before the treatment of compounds. After seeding, the tested compounds were diluted in complete media and incubated with cells for 24 h, followed by cytosol and nuclear staining for 1 h with CellTracker Green CMFDA and Hoechst 33342 (Invitrogen), respectively. For cellular tubulin staining, tubulin tracker green was used according to the manufacturer’s instructions (Invitrogen). Cellular images were recorded with an IN Cell Analyzer 6000 (GE Healthcare). After obtaining the images, the nuclear locations and cellular areas were stained with Hoechst 33342 and CMFDA, respectively, and quantitative signals from the images were calculated using a custom-made image analysis algorithm with IN Cell Developer Toolbox (GE Healthcare).

**Cluster analysis in the pathway profiling system**

All compounds were utilized at a concentration of 3 μg/mL (Natural Product Library) or 3 μM (other libraries) in the pathway profiling assays. All calculated data, including percent inhibition and percent activation number, were first normalized in each assay using the Z-scoring method and then analyzed by hierarchical clustering analysis (Ward’s method) with TIBCO Spotfire software (TIBCO).

### Table 3 Assay conditions such as cell lines, cell densities, and incubation times for cellular proliferation assays in pathway profiling

| Cell lines      | Cell density (cells/well) | Incubation time with compounds |
|-----------------|---------------------------|--------------------------------|
| HEK293T         | 5000                      | 20 h                           |
| Jurkat          | 5000                      | 20 h                           |
| MRC5            | 1000                      | 72 h                           |
| MRC5            | 3500                      | 72 h                           |
| A549            | 1000                      | 72 h                           |
| PC3             | 1000                      | 72 h                           |
| LNCaP           | 600                       | 72 h                           |
| MDA-MB-231      | 500                       | 72 h                           |

**Calculating Pearson’s correlation coefficients**

Pearson’s correlation coefficients (Rp) were calculated using the following equation:

\[
Rp = \frac{\sum_{i=1}^{N} (x_i - \bar{x})(y_i - \bar{y})}{\sqrt{\sum_{i=1}^{N} (x_i - \bar{x})^2 \sqrt{\sum_{i=1}^{N} (y_i - \bar{y})^2}}
\]

where N equals 39 assay results and \(x_i\) and \(y_i\) are the activity values of each assay in our pathway profiling database for compounds A and B, respectively.

**Tubulin polymerization assay**

Tubulin polymerization was performed using a tubulin polymerization assay kit (BK011P, Cytoskeleton). Compounds were evaluated according to the manufacturer’s instructions.

**Tubulin binding assay with its intrinsic tryptophan fluorescence**

4 μM of purified tubulin (Cytoskeleton) dissolved in general tubulin buffer (80 mM PIPES, pH 6.9, 2 mM MgCl₂, 0.5 mM EGTA) was pretreated with certain concentrations of compounds for 30 min. The intrinsic fluorescence spectra (320–400 nm) was measured with a fluorescence plate reader (EnVision; PerkinElmer) with the excitation wavelength 295 nm.

**Immunofluorescence microscopy**

MDA-MB231 cells were incubated with compounds for 6 h and 24 h to observe the cellular microtubule network and the mitotic spindles respectively. Thereafter, the cells were fixed and permeabilized as described in the past report [42]. After blocking nonspecific binding with 1 % donkey serum/PBS, the cells were incubated with the mouse monoclonal anti-α-tubulin antibody (Cell Signaling Technology) (1:1000 dilution) followed by the Alexa-488 conjugated anti-mouse IgG antibody (Invitrogen) (1:500 dilution). To visualize nuclei, the cells were incubated with Hoechst33342. For staining phospho-Histone H3, the fixed cells were treated with the rabbit monoclonal anti-phospho-Histone H3 (Ser10) antibody (Cell Signaling Technology) (1:1000 dilution) followed by the Alexa-594 conjugated anti rabbit IgG antibody (Invitrogen) (1:500 dilution). Cellular images were obtained with SP8 confocal microscopy (Leica).

**Flow cytometric analysis**

MDA-MB-231 cells were treated with compounds for 24 h, and fixed with ethanol. After fixation, cells were washed with PBS containing 2 % FCS, and, subsequently, treated with Guava Cell Cycle reagent (Merck Millipore) according to the manufacturer’s instructions. The DNA
contents were determined using a Guava easyCyte HT software (Merck Millipore).

Additional file

**Additional file 1:** Supplemental results of cell-based assays and tubulin polymerization assay. Figure S1. Measurements of fold changes in the cellular area. Figure S2. Inhibitory activity on the tubulin polymerization and the cellular microtubule network. Figure S3. The absorbance and fluorescence profiles of AMBMP. Figure S4. Measurements of growth inhibitory activity, cell cycle distribution, and mitotic spindle of MDA-MB231 cells treated with AMBMP. (DOCX 6384 kb)

Abbreviations

FDA: The Food and Drug Administration; HTS: high-throughput screening.

Acknowledgement

We thank K. Ishimaru for performing cell culture and cellular assays and S. Okubo for preparation of the recombinant plasmids. We also thank M. Oochoi, I. Miyahia and T. Kawamoto for discussions and editing. Finally, we thank N. Tarui for the encouragement to conduct this study.

Availability of data and material

The data set supporting the results of this article is included within its additional file.

Authors’ contributions

YF and OS conducted all experiments and data analysis. KK and KY conceived the study and participated in its design and drafting of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 26 August 2015 Accepted: 17 May 2016

Published online: 20 May 2016

References

1. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(10):507–19.
2. Intrigg S, Sinning C, Meyer A. Drugs; their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006;5(10):821–34.
3. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–8.
4. Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunney ME. The promise and peril of chemical probes. Nat Chem Biol. 2015;11(8):536–41.
5. Kosaka T, Okuyama R, Sun W, Ogata T, Harada J, Araki K, Izumi M, Yoshida T, Okuno A, Fujiwara T. Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry. Anal Chem. 2005;77(7):2050–5.
6. Ritix U, Super-furaga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2006;5(9):16–24.
7. Petrone PM, Simms B, Nigchi F, Lourkine E, Kutchukian P, Cornett A, Deng Z, Davies JW, Jenkins JL, Glick M. Rethinking molecular similarity: comparing compounds on the basis of biological activity. ACS Chem Biol. 2012;7(8):1399–409.
8. Michael S, Auld D, Klumpp C, Jadhav A, Zheng W, Thome N, Austin CP, Inglese J, Simeonov A. A robotic platform for quantitative high-throughput screening. ASSAY Drug Dev Technol. 2006;5:537–57.
9. King SJ, Slinger DW, Mapa FA, James J, Wu H, Smith TR, Wang Q-Y, Nyomanatnitaand P, Sipes DG, Brinker A. Pathway reporter assays reveal small molecule mechanisms of action. J Assoc Lab Autom. 2009;14(6):374–82.
10. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547–55.
11. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982;257(13):7847–51.
12. Gustafson KR, Cardellina JH, McMahon JB, Gulakowski RJ, Ishitoya S, Zsallai Z, Lewin NE, Blumberg PM, Weislow OS. A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992;35(11):1978–86.
13. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2009;5(9):616.
14. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001;11(11):S27–31.
15. McHugh Sutkowski E, Tang WJ, Broome CW, Robbins JD, Seamon KB. Regulation of forkBox interactions with type I, II, IV, and VI adenyl cyclases by Gaalpha. Biochemistry. 1994;33(43):12852–5.
16. Giorgio M, Trinei M, Migliaccio E, Pellici PG. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol. 2007;8(9):722–8.
17. Sayers CM, Papandreu I, Guttman DM, Maas NL, Diehl JA, Witze ES, Koon AC, Kourenis C. Identification and characterization of a potent activator of p53-independent cellular senescence via a small-molecule screen for modifiers of the integrated stress response. Mol Pharmacol. 2013;83(3):594–604.
18. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001;11(11):S27–31.
19. McHugh Sutkowski E, Tang WJ, Broome CW, Robbins JD, Seamon KB. Regulation of forkBox interactions with type I, II, IV, and VI adenyl cyclases by Gaalpha. Biochemistry. 1994;33(43):12852–5.
20. Cusack D, Houri AM. S-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Br J Pharmacol. 1981;72(3):443–7.
21. Middleton JP, Khan WA, Collinsworth G, Hannun YA, Medford RM. Heterogeneity of protein kinase C-mediated rapid regulation of Na/K-ATPase in kidney epithelial cells. J Biol Chem. 1993;268(21):15958–64.
22. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2009;5(9):616.
23. Whitaker RM, Wills LP, Stallions JJ, Schnellmann RG. CGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury. J Pharmacol Exp Ther. 2013;347(3):624–34.
24. Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunney ME. The promise and peril of chemical probes. Nat Chem Biol. 2015;11(8):536–41.
25. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.
26. Winters WL, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.
27. Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunney ME. The promise and peril of chemical probes. Nat Chem Biol. 2015;11(8):536–41.
28. Cusack D, Houri AM. S-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Br J Pharmacol. 1981;72(3):443–7.
29. King FJ, Slinger DW, Mapa FA, James J, Wu H, Smith TR, Wang Q-Y, Nyomanatnitaand P, Sipes DG, Brinker A. Pathway reporter assays reveal small molecule mechanisms of action. J Assoc Lab Autom. 2009;14(6):374–82.
30. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547–55.
31. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547–55.
35. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 1992;102(3):401–16.
36. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol. 2008;76(8):947–57.
37. Tierro MB, Kitchens CA, Petrik B, Graham TH, Wipf P, Xu FL, Saunders WS, Raccor BS, Balachandran R, Day BW. Microtubule Binding and disruption and induction of premature senescence by disorazole C1. J Pharmacol Exp Ther. 2009;328(3):715–22.
38. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, Caudy M, Ganapati P, Gillespie M, Kandar MR. The reactome pathway knowledgebase. Nucleic Acids Res. 2014;42(Database issue):D472–7.
39. Bunnage ME, Chekler ELP, Jones LH. Target validation using chemical probes. Nat Chem Biol. 2013;9(4):195–9.
40. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013;73(10):3087–96.
41. Martin YC, Kofron JL, Traphagen LM. Do structurally similar molecules have similar biological activity? J Med Chem. 2002;45(19):3430–8.
42. Mohan R, Banerjee M, Ray A, Manna T, Wilson L, Owa T, Bhattacharyya B, Panda D. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry. 2006;45(17):5440–9.
43. Wang Y, Debakin KM, Hug H. HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels. BMC Mol Biol. 2001;2:8–8.
44. Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI, Bartek J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev. 1997;11(11):1479–92.
45. Wang Y, Shen J, Aneranzana N, Tirapoihon W, Kaufman RJ, Prewes R. Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response. J Biol Chem. 2002;275(35):27013–20.
46. Knder KW, Vogelstein B. The Gli gene encodes a nuclear protein which binds specific sequences in the human genome. Mol Cell Biol. 1990;10(2):634–42.
47. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem. 1999;274(50):32525–9.
48. Pi R, Westermarck L, Kastem M, Heldin CH, van Zelen EJ, Nistér M, Ten Dijke P. Expression of transforming-growth-factor (TGF)-β receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-β1. Int J Cancer. 1999;80(5):756–63.
49. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korein V, Roose J, Destrée O, Clevers H. XTF-3 Transcription factor mediates β-catenin-induced axis formation in xenopus embryos. Cell. 1996;86(3):391–9.
50. Yang XO, Pappu BP, Nuriela R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS. T Helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity. 2008;28(1):29–39.